The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...